Nivocasan

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameNivocasan
Drug Alias Namenivocasan尼氟卡生尼沃卡桑nivocasanumGS-9450 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaspase inhibitors
TargetsCaspase
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLg Chemical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseHepatitis C

Other Information

ATC CodeN/A
Related LinksKEGG